

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Rabbit monoclonal D4W2Z anti-CD8

RRID:AB_2756376

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 98941, RRID:AB_2756376)

Antibody Information

URL: http://antibodyregistry.org/AB_2756376

Proper Citation: (Cell Signaling Technology Cat# 98941, RRID:AB_2756376)

Target Antigen: CD8

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IHC-Bond, IHC-P

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Rabbit monoclonal D4W2Z anti-CD8

Description: This recombinant monoclonal targets CD8

Target Organism: mouse

Clone ID: D4W2Z

Antibody ID: AB_2756376

Vendor: Cell Signaling Technology

Catalog Number: 98941

Record Creation Time: 20260218T234120+0000

Record Last Update: 20260427T062119+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Rabbit monoclonal D4W2Z anti-CD8 .

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 161 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Anastacio Da Costa Carvalho L, et al. (2026) RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer immunology research, 14(1), 90.

Mödl B, et al. (2026) TYK2 Promotes Immunosurveillance of Colorectal Cancer Liver Metastasis. Cancer research, 86(1), 80.

Zhao S, et al. (2026) Inhibition of circulating glycocholic acid-regulated signaling potentiates immune checkpoint therapy in colorectal cancer. Nature communications, 17(1).

Sardarni UK, et al. (2026) Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. Cancer research communications, 6(5), 1036.

Nguyen YTM, et al. (2026) Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer. Cell reports. Medicine, 102938.

Mateus-Tique J, et al. (2026) Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth. Cancer cell, 44(3), 534.

Sumii M, et al. (2026) Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Molecular cancer therapeutics, 25(3), 435.

Liu J, et al. (2026) Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors. Cell.

Yan X, et al. (2026) Activation of T Cell-Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy. *Cancer discovery*, 16(1), 155.

Nguyen TQA, et al. (2026) Targeting RNase H2: A dual-mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in TNBC. *Cell reports. Medicine*, 7(5), 102750.

Tu M, et al. (2026) Proteomic profiling and molecular reclassification of high-grade serous ovarian cancer identifies prognostic subtypes and immunotherapy biomarkers. *EBioMedicine*, 127, 106248.

Li C, et al. (2026) ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing. *bioRxiv : the preprint server for biology*.

Li A, et al. (2026) 5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation. *Cell reports. Medicine*, 102537.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. *Cancer immunology research*, 14(5), 771.

Lin X, et al. (2026) Spleen-targeted neoantigen mRNA vaccine induces ISG15+ CD8+ T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma. *Cell reports. Medicine*, 7(5), 102754.

Thege FI, et al. (2026) An autochthonous CRISPR activation screening platform for characterizing tissue-specific oncogene selection. *Cell reports. Medicine*, 7(5), 102759.

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. *Cell host & microbe*, 34(4), 639.

Sun L, et al. (2026) An SPP1-SOCS1 pathway constrains interferon responses in tumor-associated macrophages and shapes an immunosuppressive tumor microenvironment. *Immunity*, 59(5), 1422.

Foidart P, et al. (2026) Whole-genome doubling drives immune evasion by silencing antigen presentation. *Cancer cell*, 44(7), 1418.

Wang Y, et al. (2026) A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers. *Cell*, 189(13), 3922.